Baxia Markets
May 26, 2021

Moderna Want Adolescents Vaccinated

fundamental analysis top header -01


Moderna Inc rallies as its COVID-19 vaccine was found highly effective in adolescents from 12 to 17 years old in a recent large study. The clinical trial that included more than 3,700 young volunteers showed no cases of symptomatic COVID-19 infection in two-thirds of participants who received both doses of the vaccine, which translates into an efficacy rate of 100%.


They are now looking to get regulatory submissions around the world in early June. Shares of Moderna Inc. went up 2.63%, on what proved to be an all-around favorable trading session for the stock market, 


Graph Template (39)


The U.S. Food and Drug Administration's emergency authorization for use of the Moderna vaccine is currently limited to adults, but Moderna said Tuesday that it plans to apply in June for emergency use in adolescents. Pfizer has already been granted that approval for its vaccine.


"No significant safety concerns have been identified to date," Moderna said in its statement. Trial participants will be monitored for a year after their second dose. The trial results were announced in a news release that had no detailed data from the clinical trial, but Moderna said it plans to submit the data for publication in a peer-reviewed journal, the Times reported. Overall we can say that things are looking up for Moderna Inc.


We love to hear new ideas from traders and want to know what you think! 


If you like this topic and want to suggest future topics that you find helpful, let us know by clicking the ‘submit your feedback’ button below.


Open Live Account  


Trading foreign exchange on margin carries a high level of risk, and may not be suitable for all investors. Before deciding to trade foreign exchange you should carefully consider your investment objectives, level of experience, and risk appetite. 


Nothing contained in this website should be construed as investment advice. Any reference to an investment's past or potential performance is not, and should not be construed as, a recommendation or as a guarantee of any specific outcome or profit. 

Subscribe by Email